Biotech
With a mission to restore Earth to a healthier state through biotechnology, Colossal Biosciences develops wetware, software, and hardware technologies for habitat conservation and species restoration. Specifically, the company advances genomic sequencing, CRISPR gene editing, and reproductive technologies to pursue de-extinction of organisms like the woolly mammoth, thylacine, dodo, and dire wolf. It aims to reintroduce these species back into their former habitats for ecosystem restoration and extend technologies to prevent the extinction of other endangered populations. The company has established partnerships with academic institutions and wildlife organizations globally to advance conservation biotechnology applications. Similar to how NASA’s space exploration led to commercially viable spinoff technologies in various industries, Colossal Biosciences creates commercial spinouts to bring its conservation biotechnologies to genomics and synthetic biology markets beyond restoration efforts.
The Return of the Dire Wolf
Colossal Biosciences raises $200M at $10.2B valuation to bring back woolly mammoths
Colossal Achieves Key Milestones in Thylacine De-Extinction Effort
Plastic Degradation Company, Breaking, Emerges from Stealth with Naturally-Derived Solution to Degrade Multiple Plastics with $10.5M in Seed Funding
The business model behind resurrecting the woolly mammoth
Colossal Biosciences Secures $150M Series B and Announces Plan to De-Extinct the Iconic Dodo
Colossal Biosciences Spins Out Form Bio to Revolutionize Computational Life Sciences
A New Company With a Wild Mission: Bring Back the Woolly Mammoth
De-extinction
Science & Technology